Contrasting of ZIOPHARM Oncology Inc. (ZIOP) and ChromaDex Corporation (NASDAQ:CDXC)

This is therefore a contrasting of the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation in ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and ChromaDex Corporation (NASDAQ:CDXC). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ZIOPHARM Oncology Inc. 5 0.00 160.87M 0.67 7.67
ChromaDex Corporation 4 0.00 42.23M -0.56 0.00

Table 1 demonstrates ZIOPHARM Oncology Inc. and ChromaDex Corporation’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us the return on assets, net margins and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
ZIOPHARM Oncology Inc. 3,264,473,710.91% 112.8% 100.1%
ChromaDex Corporation 1,009,707,345.07% -139.4% -73.4%

Risk and Volatility

ZIOPHARM Oncology Inc.’s 2.61 beta indicates that its volatility is 161.00% more volatile than that of Standard & Poor’s 500. ChromaDex Corporation’s 34.00% more volatile than Standard & Poor’s 500 volatility due to the stock’s 1.34 beta.

Liquidity

10.3 and 10.3 are the respective Current Ratio and a Quick Ratio of ZIOPHARM Oncology Inc. Its rival ChromaDex Corporation’s Current and Quick Ratios are 3.3 and 2.4 respectively. ZIOPHARM Oncology Inc. has a better chance of clearing its pay short and long-term debts than ChromaDex Corporation.

Analyst Ratings

The Ratings and Recommendations for ZIOPHARM Oncology Inc. and ChromaDex Corporation are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ZIOPHARM Oncology Inc. 0 0 1 3.00
ChromaDex Corporation 0 0 1 3.00

The upside potential is 31.18% for ZIOPHARM Oncology Inc. with consensus price target of $6.5. ChromaDex Corporation on the other hand boasts of a $6 consensus price target and a 36.99% potential upside. The results from earlier shows that analysts belief suggest that ChromaDex Corporation seems more appealing than ZIOPHARM Oncology Inc.

Insider & Institutional Ownership

The shares of both ZIOPHARM Oncology Inc. and ChromaDex Corporation are owned by institutional investors at 51.3% and 19.9% respectively. ZIOPHARM Oncology Inc.’s share held by insiders are 0.3%. Competitively, 2.4% are ChromaDex Corporation’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ZIOPHARM Oncology Inc. -0.96% 23.44% 11.93% 22.86% 58.77% 175.94%
ChromaDex Corporation 5.08% 28.36% -4.14% -6.93% 18.42% 11.52%

For the past year ZIOPHARM Oncology Inc. has stronger performance than ChromaDex Corporation

Summary

ZIOPHARM Oncology Inc. beats ChromaDex Corporation on 10 of the 11 factors.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.